Freestone Grove Partners LP bought a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 18,192 shares of the biopharmaceutical company's stock, valued at approximately $1,424,000.
A number of other institutional investors have also recently added to or reduced their stakes in the company. Horizon Investment Services LLC acquired a new position in Halozyme Therapeutics during the second quarter worth about $2,254,000. Mizuho Markets Americas LLC lifted its holdings in Halozyme Therapeutics by 270.8% in the 4th quarter. Mizuho Markets Americas LLC now owns 1,268,673 shares of the biopharmaceutical company's stock valued at $85,382,000 after acquiring an additional 926,526 shares during the last quarter. Chase Investment Counsel Corp acquired a new stake in Halozyme Therapeutics in the 2nd quarter valued at about $2,035,000. Aurora Investment Counsel bought a new position in shares of Halozyme Therapeutics during the 2nd quarter valued at about $1,427,000. Finally, Northwestern Mutual Wealth Management Co. boosted its position in shares of Halozyme Therapeutics by 19,326.4% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 85,476 shares of the biopharmaceutical company's stock valued at $5,753,000 after purchasing an additional 85,036 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of research firms recently commented on HALO. UBS Group reiterated a "buy" rating and issued a $90.00 target price on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Wells Fargo & Company increased their target price on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the company an "equal weight" rating in a research note on Friday, August 7th. HC Wainwright raised their target price on shares of Halozyme Therapeutics from $95.00 to $115.00 and gave the stock a "buy" rating in a report on Friday, August 7th. Weiss Ratings lowered shares of Halozyme Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a research report on Friday, August 14th. Finally, Wall Street Zen raised Halozyme Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 8th. Nine analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Halozyme Therapeutics has an average rating of "Moderate Buy" and an average target price of $91.20.
Check Out Our Latest Research Report on HALO
Insider Transactions at Halozyme Therapeutics
In other news, Director Bernadette Connaughton sold 1,626 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $102.80, for a total value of $167,152.80. Following the transaction, the director directly owned 40,418 shares of the company's stock, valued at $4,154,970.40. This trade represents a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the business's stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $547,800.00. Following the sale, the director owned 14,462 shares in the company, valued at $1,084,650. This represents a 33.56% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 64,103 shares of company stock valued at $5,226,496 over the last ninety days. Corporate insiders own 2.50% of the company's stock.
Halozyme Therapeutics Trading Down 1.5%
NASDAQ:HALO opened at $105.35 on Friday. The stock has a fifty day simple moving average of $87.01 and a 200 day simple moving average of $74.78. The firm has a market capitalization of $11.96 billion, a price-to-earnings ratio of 31.45, a price-to-earnings-growth ratio of 0.42 and a beta of 0.85. Halozyme Therapeutics, Inc. has a 1-year low of $61.22 and a 1-year high of $109.66. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50.
Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The firm had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. During the same quarter in the previous year, the company earned $1.54 EPS. The business's revenue for the quarter was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 7.77 earnings per share for the current year.
About Halozyme Therapeutics
(
Free Report)
Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.
The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Halozyme Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Halozyme Therapeutics wasn't on the list.
While Halozyme Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
